secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0000950170-25-035482
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q4 2024 net loss $12.7M; workforce cut 50%; pauses CAR-T programs; EBVALLO BLA resubmission ongoing
--------------------------------------------------------------------------------

- Net loss of $12.7M ($1.19/share) for Q4 2024 vs $60.5M loss in Q4 2023; full year loss $85.4M.
- Cash and equivalents $42.5M at Dec 31, 2024; entered non-binding term sheet for up to $15M equity line with Redmile Group.
- Workforce reduced ~50%, retaining ~35 personnel to focus on EBVALLO BLA resubmission and CAR-T wind-down.
- Paused ATA3219 and ATA3431 CAR-T programs; discontinued Phase 1 NHL study for ATA3219.
- FDA CRL in Jan 2025 cited third-party manufacturing issues; clinical hold on EBVALLO; regulatory update expected in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/0000950170-25-035482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-20250307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer